Quantitative Volume and Density Response Assessment: Sarcoma and HCC as a Model

描述(由申请人提供)：这项研究的目标是开发基于肿瘤体积和坏死率变化的CT成像的癌症治疗新的反应评估。目前用于疗效评估的RECIST标准和分界值不是以证据为基础的，可能无法检测与靶向、非细胞毒性治疗的临床反应相关的肿瘤变化。这项研究将使用两种类型的肿瘤来寻求概念的证据，在这两种类型的肿瘤中，RECIST已知与肿瘤的治疗反应和临床结果相关性较差。肝细胞癌是世界上最常见的恶性肿瘤之一，肉瘤虽然罕见，但与许多其他异质癌症一样，具有相同的分子变化，是药物发现中研究的经典癌症。目的1将证明新的自动分割算法的辅助可以减少放射科医生测量肺、肝和淋巴癌的变异性。这一目标将使用SARC 011已经收集的276名患者的图像，SARC 011是一项大型的肉瘤II期多中心临床试验。目的2将在SARC011和CALGB 80802中将肿瘤体积和坏死率与临床结果相关联，这是一项肝细胞癌的阶段试验，估计有480名患者登记。这项拟议的研究将首先制定基于定量生物标记物(肿瘤体积和坏死率)的标准，然后使用一致性概率估计将这些标准的预测价值与当前的临床标准进行比较。目的3将探索这些标准与其他生化标记物的相关性，并使用一致性概率估计来确定成像生物标记物与生化标记物的组合是否比单独使用提供更好的患者生存预测。这一目标将使用SARC011和CALGB 80802的三项配套生物学研究的数据。新标准的制定和验证将具有重大的健康意义，因为有证据表明体积和坏死的变化是反应或进展的早期生物标志物，这将指导临床试验和患者治疗。新标准将广泛应用于临床实践，因为CT是最常见的癌症成像方式，新算法运行在流行的成像平台上，这种方法将减少放射科医生所需的时间。相关性(参见说明书)；当测试癌症的新疗法时，测量患者肿瘤的图像以确定治疗是否有效。通过开发一种更好的方法来衡量治疗引起的肿瘤变化，这项研究将有助于发现抗癌药物，并帮助患者匹配最适合他们的治疗方法。

DESCRIPTION (provided by applicant): The goal of this research is to develop new response assessments for cancer treatment based on CT imaging of changes in tumor volume and necrosis fraction. Current RECIST criteria and cut-off values for response assessment are not evidence-based and may fail to detect the tumor changes associated with clinical response to targeted, non-cytotoxic treatments. This study will seek a proof of concept using two types of tumors in which RECIST is known to correlate poorly with tumor response to treatment and clinical outcome. HCC is one of the most common malignancies worldwide, and sarcomas, though rare, carry the same molecular alterations as many other heterogeneous cancers and are the classic cancer studied in drug discovery. Aim 1 will demonstrate that assistance from new automated segmentation algorithms can reduce the variability in radiologists' measurement of lung, liver, and lymph tumors. This aim will use images from 276 patients already collected by SARC 011, a large phase II multicenter clinical trial of sarcoma. Aim 2 will correlate tumor volume and necrosis fraction with clinical outcome in SARC 011 and CALGB 80802, a phase trial of HCC with an estimated enrollment of 480 patients. The proposed research will first develop criteria based on quantitative biomarkers (tumor volume and necrosis fraction) and then compare the predictive value of these criteria to the current clinical standard using a concordance probability estimate. Aim 3 will explore the correlation of these criteria to other biochemical markers, and use a concordance probability estimate to determine whether the combination of imaging biomarkers with biochemical markers affords superior prediction of patient survival as compared to either alone. This aim will use data from three companion biology studies of SARC 011 and CALGB 80802. Development and validation of the new criteria will have substantial health significance because evidence that volume and necrosis changes are early biomarkers of response or progression will guide clinical trials and patient treatment. The new criteria will be widely applicable to clinical practice because CT is the most common imaging modality for cancer, the new algorithms run on popular imaging platforms, and this method will reduce the time required by radiologists. RELEVANCE (See instructions); When new treatments for cancer are being tested, images of the patients' tumor are measured to determine whether the treatment is working. By developing a better way to measure tumor changes caused by treatment, this research will aid the discovery of cancer drugs and help match patients to the treatment that works best for them.